What is ImmuneBridge?
ImmuneBridge is at the forefront of cell therapy innovation, specializing in the development of high-quality treatments derived from umbilical cord blood stem cells. The company employs advanced machine learning for efficient donor screening and scalable manufacturing processes. By addressing critical challenges in cell therapy, such as cost and manufacturability, ImmuneBridge aims to deliver safe and effective therapies for a range of previously untreatable diseases. Their collaborative approach with academic and industry partners is key to creating groundbreaking treatments and achieving global accessibility and affordability.
How much funding has ImmuneBridge raised?
ImmuneBridge has raised a total of $12M across 1 funding round:
Angel/Seed
$12M
Angel/Seed (2023): $12M with participation from Gaingels, One Way Ventures, Merck Ventures, and Insight Partners
Key Investors in ImmuneBridge
Gaingels
Gaingels is a leading investment syndicate supporting the LGBTQ community and allies, investing in high-growth companies with inclusive teams across various sectors from Seed to Growth/pre-IPO stages.
One Way Ventures
One Way Ventures focuses on supporting immigrant founders in building high-impact global companies, investing in exceptional startups and fostering opportunities regardless of birthplace.
Merck Ventures
M Ventures, the strategic corporate venture capital arm of Merck, invests globally in innovative technologies and products with the potential to significantly impact Merck's core business areas, with a focus on early-stage investing and company creation.
What's next for ImmuneBridge?
The recent major enterprise-level funding signifies a pivotal stage for ImmuneBridge, likely enabling the company to scale its operations, expand its research and development pipeline, and potentially pursue clinical trials or market entry for its proprietary cell therapies. This strategic backing from prominent investors suggests confidence in ImmuneBridge's technology and its potential to disrupt the healthcare landscape. The company is poised to leverage this investment to further its mission of making advanced cell therapies a reality for a broader patient population.
See full ImmuneBridge company page
